Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Amiloride. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCNN1A known ✓ | P37088 | 1/20 | 1.00 |
| ▸ | PLAU | P00749 | 11/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 6/20 | 1.00 |
| ▸ | SLC9A1 | P19634 | 6/20 | 1.00 |
| ▸ | TSHR | P16473 | 5/20 | 1.00 |
| ▸ | SLC9A5 | Q14940 | 5/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | GLA | P06280 | 3/20 | 1.00 |
| ▸ | HPGD | P15428 | 3/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | FTO | Q9C0B1 | 2/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 2/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amiloride SCHEMBL29531132 | 1.00 | PLAU (1.00) | PLAUCYP1A2SLC9A1TSHRSLC9A5 | |
| Amiloride SCHEMBL4155066 | 0.98 | ALDH1A1 (1.00) | PLAUCYP1A2SLC9A1TSHRSLC9A5 | |
| Amiloride SCHEMBL136682 | 0.96 | PLAU (0.93) | PLAUCYP1A2SLC9A1TSHRSLC9A5 | |
| Amiloride SCHEMBL871514 | 0.95 | PLAU (0.90) | PLAUCYP1A2SLC9A1TSHRSLC9A5 | |
| SCHEMBL2690754 | 0.91 | PLAU (0.83) | PLAUCYP1A2SLC9A1TSHRSLC9A5 | |
| SCHEMBL13902826 | 0.86 | PLAU (0.75) | PLAUCYP1A2SLC9A1TSHRSLC9A5 | |
| SCHEMBL14153334 | 0.86 | PLAU (0.75) | PLAUCYP1A2SLC9A1TSHRSLC9A5 | |
| SCHEMBL15033062 | 0.86 | PLAU (0.75) | PLAUCYP1A2SLC9A1TSHRSLC9A5 | |
| SCHEMBL10087514 | 0.84 | PLAU (0.73) | PLAUCYP1A2SLC9A1TSHRSLC9A5 | |
| SCHEMBL13104159 | 0.83 | PLAU (0.71) | PLAUCYP1A2SLC9A1TSHRSLC9A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 34628 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747611-A1 | OPTICAL ELECTRODE ANALYTE DETECTION SYSTEM AND METHODS OF USE | Vital Biosciences Inc. (CA) | 2026-05-27 | — | — | EP | claimed |
| WO-2026106917-A1 | EDIBLE TRANSMUCOSAL DRUG DELIVERY METHOD USING AN INTERMEDIATE CAPSULE AS A TEMPORARY VESSEL | BioPhysics Pharma, Inc. (US) | 2026-05-21 | — | — | WO | claimed |
| EP-3411059-B1 | METHOD TO ENHANCE THE EFFICIENCY OF SYSTEMIC AAV GENE DELIVERY TO THE CENTRAL NERVOUS SYSTEM | UNIV MASSACHUSETTS (US) | 2026-05-06 | — | — | EP | claimed |
| US-12605345-B2 | Transdermal drug delivery system | BioPhysics Pharma, Inc. (US) | 2026-04-21 | — | — | US | claimed |
| EP-4722714-A1 | SIMULTANEOUS ANALYSIS OF FOOD-BORNE DOPING SUBSTANCES USING LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (VFD: VACCINE FOR FOODBORNE DOPING) | Korea Institute of Science and Technology (KR) | 2026-04-08 | — | — | EP | claimed |
| US-20260076961-A1 | COMBINATION TREATMENTS | Celex Oncology Innovations Limited (GB) | 2026-03-19 | — | — | US | claimed |
| EP-4710928-A2 | METHODS OF TREATING IGA NEPHROPATHY WITH ATRASENTAN | Chinook Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | claimed |
| CN-121570404-A | Whitening and freckle-removing composition and preparation method and application thereof | 浙江大医德美生物科技有限公司 | 2026-02-27 | — | — | CN | claimed |
| EP-4699655-A2 | COMPOUNDS | TMEM16A LIMITED (GB) | 2026-02-25 | — | — | EP | claimed |
| US-20250387389-A1 | METHODS OF TREATING DISEASE WITH LEVOKETOCONAZOLE | XERIS PHARMACEUTICALS, INC. (US) | 2025-12-25 | — | — | US | claimed |
| EP-0049842-A2 | Substituted enantholactam derivatives, a process for the preparation and a pharmaceutical composition useful in the treatment of hypertension comprising the same, and intermediates | MERCK & CO. INC. (US) | 1982-04-21 | — | — | EP | claimed |
| EP-0049505-A2 | Substituted caprolactam derivatives, a process for preparing and a pharmaceutical composition containing the same, and intermediates | MERCK & CO. INC. (US) | 1982-04-14 | — | — | EP | claimed |
| EP-0049506-A1 | N-carboxyalkyl dipeptides, a process for preparing and a pharmaceutical composition comprising the same | MERCK & CO. INC. (US) | 1982-04-14 | — | — | EP | claimed |
| EP-0046291-A2 | Substituted caprolactam derivatives as antihypertensives, process for preparing them, pharmaceutical composition containing them, and intermediates | MERCK & CO. INC. (US) | 1982-02-24 | — | — | EP | claimed |
| US-4311697-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1982-01-19 | — | — | US | claimed |
| EP-0036145-A1 | An orally administered drug form comprising a polar bioactive agent and an adjuvant | INTERx RESEARCH CORPORATION (US) | 1981-09-23 | — | — | EP | claimed |
| EP-0031561-A2 | A rectally administered suppository comprising a drug and an adjuvant | MERCK & CO. INC. (US) | 1981-07-08 | — | — | EP | claimed |
| US-4217347-A | MERCAPTOALKYL ALKANOYLPROLINES AND A DIURETIC | E. R. SQUIBB & SONS, INC. (US) | 1980-08-12 | — | — | US | claimed |
| EP-0012401-A1 | Carboxyalkyl dipeptide derivatives, process for preparing them and pharmaceutical composition containing them | MERCK & CO. INC. (US) | 1980-06-25 | — | — | EP | claimed |
| US-4178374-A | SUBSTITUTED 1,2,5-THIADIAZOLE B-ADRENERGIC BLOCKING AGENT, PYRAZINE AND/OR THIAZIDE DIURETIC, TREATMENT OF HYPERTENSION | MERCK & CO., INC. (US) | 1979-12-11 | — | — | US | claimed |